NASDAQ: AZNAstrazeneca Plc Stock Forecast, Predictions & Price Target
Analyst price target for AZN
Based on 4 analysts offering 12 month price targets for Astrazeneca Plc.
Min Forecast
$52.50+2.98%%
Avg Forecast
$63.23+24.02%%
Max Forecast
$69.40+36.13%%
Should I buy or sell AZN stock?
Strong Buy
Strong Buy
6 analysts 85.71%%
Buy
0 analysts 0%%
Hold
1 analysts 14.29%%
Sell
0 analysts 0%%
Strong Sell
0 analysts 0%%
Forecast return on equity
Is AZN forecast to generate an efficient return?
Company
41.01%%
Industry
65.68%%
Market
-6.64%%
AZN's Return on Equity is forecast to be high in 4 years (41.01%%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is AZN forecast to generate an efficient return on assets?
Company
8.37%%
Industry
15.48%%
Market
11.54%%
AZN is forecast to generate lower Return on Assets (8.37%%) than the US Drug Manufacturers - General industry average (15.48%%)
Forecast
AZN earnings per share forecast
What is AZN's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$2.02+145.85%%
Avg 2 year Forecast
$2.57+212.93%%
Avg 3 year Forecast
$3.14+282.93%%
AZN's earnings are forecast to grow at an exceptional rate of 56.35%% per year
Forecast
AZN revenue forecast
What is AZN's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$26.3B+2.37%%
Avg 2 year Forecast
$29.9B+16.48%%
Avg 3 year Forecast
$33.5B+30.49%%
AZN's revenue is forecast to grow at a rate of 9.28%% per year, which is not exceptional
Forecast
AZN earnings growth forecast
How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
56.35%%
Industry
18.94%%
Market
13.11%%
AZN's earnings are forecast to grow faster (56.35%% per year) than the US Drug Manufacturers - General industry average (18.94%%)
Forecast
AZN's earnings are forecast to grow faster (56.35%% per year) than the US market average (13.11%%)
Forecast
AZN revenue growth forecast
How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
9.28%%
Industry
6.35%%
Market
5.29%%
AZN's revenues are forecast to grow faster (9.28%% per year) than the US Drug Manufacturers - General industry average (6.35%%)
Forecast
AZN's revenues are forecast to grow faster (9.28%% per year) than the US market average (5.29%%)
Forecast
Astrazeneca Stock Forecast FAQ
Is Astrazeneca Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 7 Wall Street analysts covering (NASDAQ: AZN) stock is to Strong Buy AZN stock.
Out of 7 analysts, 6 (85.71%%) are recommending AZN as a Strong Buy, 0 (0%%) are recommending AZN as a Buy, 1 (14.29%%) are recommending AZN as a Hold, 0 (0%%) are recommending AZN as a Sell, and 0 (0%%) are recommending AZN as a Strong Sell.
What is AZN's Price Target?
According to 4 Wall Street analysts that have issued a 1 year AZN price target, the average AZN price target is $63.23, with the highest AZN stock price forecast at $69.40 and the lowest AZN stock price forecast at $52.50.
On average, Wall Street analysts predict that Astrazeneca's share price could reach $63.23 by Oct 13, 2021. The average Astrazeneca stock price prediction forecasts a potential upside of 24.02%% from the current AZN share price of $50.98.
What is AZN's earnings growth forecast for 2020-2022?
(NASDAQ: AZN) Astrazeneca's forecast annual earnings growth rate of 56.35%% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 18.94%%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 13.11%%.
Astrazeneca's earnings in 2020 is $2,045,000,000.On average, 5 Wall Street analysts forecast AZN's earnings for 2020 to be $2,644,992,000, with the lowest AZN earnings forecast at $2,571,520,000, and the highest AZN earnings forecast at $2,689,600,000. On average, 5 Wall Street analysts forecast AZN's earnings for 2021 to be $3,366,592,000, with the lowest AZN earnings forecast at $3,148,800,000, and the highest AZN earnings forecast at $3,608,000,000.
In 2022, AZN is forecast to generate $4,119,680,000 in earnings, with the lowest earnings forecast at $3,817,920,000 and the highest earnings forecast at $4,277,120,000.
What is AZN's revenue growth forecast for 2020-2022?
(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 9.28%% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.35%%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 5.29%%.
Astrazeneca's revenue in 2020 is $25,699,000,000.On average, 3 Wall Street analysts forecast AZN's revenue for 2020 to be $34,516,122,240,000, with the lowest AZN revenue forecast at $34,172,352,000,000, and the highest AZN revenue forecast at $34,744,384,000,000. On average, 3 Wall Street analysts forecast AZN's revenue for 2021 to be $39,273,661,216,000, with the lowest AZN revenue forecast at $37,592,184,960,000, and the highest AZN revenue forecast at $40,358,432,000,000.
In 2022, AZN is forecast to generate $43,996,625,056,000 in revenue, with the lowest revenue forecast at $40,574,964,480,000 and the highest revenue forecast at $45,920,000,000,000.
What is AZN's Earnings Per Share (EPS) forecast for 2020-2022?
(NASDAQ: AZN) Astrazeneca's current Earnings Per Share (EPS) is $0.82. On average, analysts forecast that AZN's EPS will be $2.02 for 2020, with the lowest EPS forecast at $1.96, and the highest EPS forecast at $2.05. On average, analysts forecast that AZN's EPS will be $2.57 for 2021, with the lowest EPS forecast at $2.40, and the highest EPS forecast at $2.75. In 2022, AZN's EPS is forecast to hit $3.14 (min: $2.91, max: $3.26).
What is AZN's forecast return on equity (ROE) for 2020-2023?
(NASDAQ: AZN) forecast ROE is 41.01%%, which is considered strong.
What is AZN's forecast return on assets (ROA) for 2020-2023?
(NASDAQ: AZN) forecast ROA is 8.37%%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.48%%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
